The Psychiatric Record | Clinical Evidence
The medication plan that accompanies recovery from a first manic episode can acquire momentum. At later visits, continuing it may be reasonable, but the record should still explain what each treatment is intended to accomplish and how the longer-term decision will be revisited.
A focused new population
The BD-CAUSAL target trial emulation examined 371 people with bipolar I disorder after a first manic episode with psychotic symptoms, representing 465 eligible treatment initiations. Participants came from cohorts in North America, Chile, and Spain. The main outcome was hospitalization or an emergency-department visit for any psychiatric reason over two years. This is narrower than all symptomatic relapse and does not specify the polarity of an episode.
Treatment strategy | Estimated two-year risk (95% CI) |
|---|---|
Mood stabilizer monotherapy | 42.3% (32.5 to 61.1) |
Second-generation antipsychotic monotherapy | 49.5% (42.4 to 60.6) |
Combination therapy | 42.2% (33.3 to 52.5) |
Compared with second-generation antipsychotic monotherapy, the reported risk difference was -7.3 percentage points (95% CI, -15.8 to -1.4) for mood stabilizer monotherapy and -7.4 points (-16.0 to -2.1) for combination therapy. The corresponding risk ratios were 0.82 (0.63 to 0.97) and 0.82 (0.63 to 0.91). The abstract reports similar risks for mood stabilizer monotherapy and combination therapy; it does not establish equivalence or a benefit from adding an antipsychotic to a mood stabilizer.
This was not a randomized trial. Treatment choices may reflect differences in illness, tolerability, clinician judgment, or other factors incompletely captured in the analysis. The abstract describes eligibility assessment at each person-visit, but the full methods are needed to understand how repeated contributions from one person were handled. The larger number of treatment initiations does not, by itself, establish that the analysis used cloning.
The abstract does not identify which individual mood stabilizers were included or report separate manic and depressive outcome estimates. These omissions limit medication-specific and polarity-specific interpretation. As discussed in our September 18 article on long-acting injections and relapse polarity, an overall psychiatric outcome cannot answer every question about depression prevention. The studies examine different treatment comparisons and should not be treated as interchangeable evidence.
Three questions for the maintenance review
What was the original purpose? Recover the reasoning behind the acute regimen. If several medicines were introduced during a crisis, a later medication list may not show which symptom or problem each was meant to address. An explicit account makes the continuation discussion more understandable.
What is the current purpose? Describe the present goals and the evidence used to support them. Prevention of future episodes, remaining symptoms, tolerability, and the patient's own priorities all belong in the discussion. When a combination is continuing, state the intended contribution of each medicine. Continuing a treatment and changing it both need a clinical rationale.
When will the decision be revisited? A plan can specify what information or clinical change would prompt review. This is more useful than allowing the absence of a new crisis to become the only explanation for an unchanged regimen.
A better handoff than an automatic switch
The study does not provide instructions to stop an antipsychotic or to choose a particular mood stabilizer. Any treatment change requires an individualized review, including the episode history, benefits, adverse effects, and relevant safety considerations. The immediate editorial lesson is to make maintenance reasoning visible.
A concise handoff can state the episode being treated, what improved, the intended role of each continuing medicine, and what remains uncertain. It can also record the patient's understanding and questions. That gives the next clinician a reasoned plan to evaluate rather than an inherited list to perpetuate.
The new findings warrant careful examination of the full paper. Meanwhile, the distinction between an acute response and a documented maintenance strategy is already a useful question to bring to the follow-up.
Source and reading note
Szmulewicz and colleagues. Comparative effectiveness of mood stabiliser monotherapy versus second-generation antipsychotic monotherapy versus combination therapy for continuation and maintenance treatment after a first episode of psychotic mania in North America, Chile, and Spain: a target trial emulation using data from the BD-CAUSAL Collaboration. The Lancet Psychiatry, 2026. DOI: 10.1016/S2215-0366(26)00239-7. The review questions are editorial synthesis, not a trial-tested intervention.
Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. This article summarizes an observational study at abstract level and does not recommend starting, stopping, or changing any medication.